European Prevention of Alzheimer’s Dementia (EPAD)
The European Prevention of Alzheimer’s Dementia (EPAD) consortium is one of the largest public-private partnerships in the history of AD research. In 2016, EPAD began a longitudinal cohort study (LCS) that screened more than 2,000 participants to collect a wide range of cognitive, clinical, neuroimaging and biomarker data to help further our understanding of the early stages of Alzheimer’s disease. From these 2,000 participants, EPAD followed up with 1,225 after one year, 421 after two years and 121 after three years before funding from the Innovative Medicine Initiative (IMI) ceased. Several national initiatives are in development to ensure long-term follow-up on all EPAD participants across Europe.
The current EPAD database is open access, ensuring the use of the data for the Alzheimer’s disease research community worldwide. Data access is free to all researchers.ACCESS AND DATA
The EPAD LCS Research Access Process (ERAP) was set up and designed to give academic researchers, institutions and companies from all over the world a simple, quick way to access the data collected during the longitudinal cohort study.
All four databases have been released:
- EPAD LCS V500.0, which includes data from the first 500 people to enter the cohort;
- EPAD LCS V1500.0, which includes data from the first 1,500 people to enter the cohort;
- EPAD LCS V500.1, which includes updated data from the first 500 participants, including one-year follow-up data; and
- Version.IMI (V.IMI), which includes the final longitudinal data including cognitive (e.g., RBANS, MMSE, CDR), clinical (e.g., medical history, medications), biomarker (APOE, [CSF] Aβ42, tau) and neuroimaging and lifestyle risk factor (sleep, diet, traumatic life events) data sets from the over 2,000 participants of the EPAD LCS.
All data sets from the EPAD LCS study are now available in the AD Workbench and will provide even greater value to the global neuroscience research community. Moreover, a very large BioBank is available for sample access that includes CSF, blood and saliva from all participant visits.